Skip directly to content



Pfizer is strongly committed to research in the Inflammation area and supports medical innovation in The Netherlands through this Competitive Investigator Research Award Program.

The Dutch ASPIRE Inflammation Competitive Research Program (I-CRP) aims to inspire and fund innovative research projects in the field of inflammation which may further enhance the understanding of certain rheumatology and dermatology conditions and contribute to excellence in patient care.

An independent committee of European medical experts in the field of Inflammation will review the research proposals and select the grant recipients.

This program provides research grants for studies designed and conducted by non-Pfizer physicians and scientists.


Pfizer invites investigators to apply for the ASPIRE I-CRP through submission of research proposals with the primary objective to further enhance the understanding of certain rheumatology and dermatology conditions and contribute to excellence in patient care.

  • It is anticipated that individual awards up to €100,000 will be made. Funding will be spread over the lifetime of the project
  • The grants will be non-renewable and will be for research to be undertaken within a time period of a maximum of 12-18 months
  • Due to the competitive nature of the awards, Pfizer cannot provide any additional funding and/or drug support beyond what has been requested and approved by the external review panel
  • The deadline for submission is February 27th at 24.00


For 2014, applications in the following high interest areas will be considered:

Rheumatoid Arthritis (RA)

  • Role of Imaging in treatment monitoring
  • Health economic aspects of anti TNF treatment
  • Immunogenicity
  • Adherence
  • Patient Reported Outcomes
  • Cardiovascular Co-morbidities

Ankylosing Spondylitis (AS)

  • Anti TNF Monotherapy
  • Immunogenicity
  • Role of Imaging in early diagnosis
  • Role of Imaging in treatment monitoring
  • Risk factors to predict transitioning of Non- radiographic Axial SpA in to Ankylosing Spondylitis
  • Health economic aspects of anti TNF treatment
  • Patient Reported Outcomes

Psoriatic Arthritis (PsA)

  • Imaging in early diagnosis
  • Early diagnosis and treatment
  • Anti TNF Monotherapy
  • Immunogenicity
  • Treatment monitoring
  • Patient Reported Outcomes
  • Axial disease in PsA
  • Co-morbidities

Psoriasis (PsO)

  • Long-term safety and efficacy of etanercept (analysis of existing data/retrospective studies)
  • Patient Reported Outcomes
  • Co-morbidities
  • Immunogenicity

Juvenile Idiopathic Arthritis (JIA)

  • Monitoring disease activity in JIA
  • Health economic aspects of anti TNF treatment
  • Transitioning care into adult rheumatology

Independent External Review Committee

The ASPIRE I-CRP applications will be reviewed by an independent, external review committee comprised of medical and scientific experts. The independent, external review committee will evaluate all proposals and select those to be awarded. Titles of the awarded projects and names of investigators will be made public through this web page and via the Dutch Society of Rheumatologists (NVR).


Pfizer is funding awards up to €100,000 each for a time period of 12-18 months. It is expected that the results will be presented at scientific meetings and published in peer reviewed journals.


  • Application submission start:December 15th, 2013
  • Application deadline:February 27th 2014, 24.00 hrs
  • Applications reviewed by commission:April 16th, 2014
  • Awards announcement:May 16th, 2014
  • Research period:June 2014 onwards
  • Awards official announcement:September, 2014